Skip to content


Ebanga™ (ansuvimab-zykl, formerly mAb114) a human monoclonal antibody indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.

On 21 December 2020, Ridgeback obtained FDA approval for Ebanga™. In July 2022, Ridgeback entered into an agreement with Emergent BioSolutions Inc. where Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga™ in the United States and Canada, and Ridgeback will serve as the global access partner for Ebanga™, ensuring it remains available to patients free of charge in Ebola-stricken countries.

More Information

For more information EBANGA™ including the U.S. Prescribing Information, please go to:

Development Pipeline

(ansuvimab-zykl, mAb114)


Ridgeback would like to acknowledge and thank our collaborators on the EBANGA™ (ansuvimab-zykl, mAb114) development program:

  • Biomedical Advanced Research and Development Authority (BARDA)
  • U.S. Department of Health and Human Services (HHS)
  • National Institute for Allergy & Infectious Diseases (NIAID)
  • National Institutes of Health (NIH)
  • Office of the Assistant Secretary for Preparedness and Response (ASPR)
  • The Vaccine Research Center
  • Institut National de Recherche Biomédicale de Kinshasa, République Démocratique du Congo
  • The Vaccine Clinical Materials Program (VCMP); Frederick National Laboratory for Cancer Research; sponsored by the National Cancer Institute (NCI);
  • World Health Organization (WHO)
  • The Alliance for International Medical Action (ALIMA)
  • Médecins Sans Frontières (MSF)
  • International Medical Corps (IMC)
  • Samaritan's Purse